Enrolling by invitationNCT04824040
Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF
Studying Dysferlin-related limb-girdle muscular dystrophy R2
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Artgen Biotech
- Principal Investigator
- Roman Deev, PhDHSCI, Russia
- Enrollment
- 100 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2020 – 2027
Study locations (1)
- Human Stem Cells Institute, Moscow, Russia
Collaborators
Genotarget
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04824040 on ClinicalTrials.gov